BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31513380)

  • 1. Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA.
    Finlay DB; Manning JJ; Ibsen MS; Macdonald CE; Patel M; Javitch JA; Banister SD; Glass M
    ACS Chem Neurosci; 2019 Oct; 10(10):4350-4360. PubMed ID: 31513380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB
    Ryalls B; Patel M; Sparkes E; Banister SD; Finlay DB; Glass M
    Biochem Pharmacol; 2024 Apr; 222():116052. PubMed ID: 38354957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism.
    Finlay DB; Mackie W; Webb HDJ; Thomsen LR; Nimick M; Rosengren RJ; Marusich JA; Glass M; Wiley JL
    Pharmacol Biochem Behav; 2023 Feb; 223():173530. PubMed ID: 36805861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues.
    Banister SD; Longworth M; Kevin R; Sachdev S; Santiago M; Stuart J; Mack JB; Glass M; McGregor IS; Connor M; Kassiou M
    ACS Chem Neurosci; 2016 Sep; 7(9):1241-54. PubMed ID: 27421060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex-dependent pharmacological profiles of the synthetic cannabinoid MMB-Fubinaca.
    Oliveira da Cruz JF; Ioannidou C; Pagano Zottola AC; Muguruza C; Gomez-Sotres P; Fernandez M; Callado LF; Marsicano G; Busquets-Garcia A
    Addict Biol; 2021 May; 26(3):e12940. PubMed ID: 32744799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of AMB-FUBINACA metabolism and CB
    Webb HDJ; Finlay DB; Chen S; Vernall AJ; Sparkes E; Banister SD; Rosengren RJ; Glass M
    Forensic Toxicol; 2023 Jan; 41(1):114-125. PubMed ID: 36652070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
    Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11.
    Kevin RC; Cairns EA; Boyd R; Arnold JC; Bowen MT; McGregor IS; Banister SD
    Front Psychiatry; 2022; 13():1048836. PubMed ID: 36590635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB
    Patel M; Grimsey NL; Banister SD; Finlay DB; Glass M
    Pharmacol Res Perspect; 2023 Dec; 11(6):e01157. PubMed ID: 38018694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
    Grafinger KE; Cannaert A; Ametovski A; Sparkes E; Cairns E; Banister SD; Auwärter V; Stove CP
    Drug Test Anal; 2021 Jul; 13(7):1402-1411. PubMed ID: 33769699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.
    Gamage TF; Farquhar CE; Lefever TW; Marusich JA; Kevin RC; McGregor IS; Wiley JL; Thomas BF
    J Pharmacol Exp Ther; 2018 May; 365(2):437-446. PubMed ID: 29549157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market.
    Brandon AM; Antonides LH; Riley J; Epemolu O; McKeown DA; Read KD; McKenzie C
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33807614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L-valine or L-tert-leucine.
    Wouters E; Mogler L; Cannaert A; Auwärter V; Stove C
    Drug Test Anal; 2019 Aug; 11(8):1183-1191. PubMed ID: 31021521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA.
    Banister SD; Moir M; Stuart J; Kevin RC; Wood KE; Longworth M; Wilkinson SM; Beinat C; Buchanan AS; Glass M; Connor M; McGregor IS; Kassiou M
    ACS Chem Neurosci; 2015 Sep; 6(9):1546-59. PubMed ID: 26134475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of human T-type calcium channels by synthetic cannabinoid receptor agonists in vitro.
    Bladen C; Mirlohi S; Santiago M; Longworth M; Kassiou M; Banister S; Connor M
    Neuropharmacology; 2021 Apr; 187():108478. PubMed ID: 33600843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA.
    Kevin RC; Wood KE; Stuart J; Mitchell AJ; Moir M; Banister SD; Kassiou M; McGregor IS
    J Psychopharmacol; 2017 Jun; 31(6):757-769. PubMed ID: 28093016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of structurally novel G protein biased CB
    Ford BM; Franks LN; Tai S; Fantegrossi WE; Stahl EL; Berquist MD; Cabanlong CV; Wilson CD; Penthala NR; Crooks PA; Prather PL
    Pharmacol Res; 2017 Nov; 125(Pt B):161-177. PubMed ID: 28838808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids.
    Gatch MB; Forster MJ
    Neurotoxicology; 2019 Jan; 70():72-79. PubMed ID: 30439379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.